Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58


Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.

Goepfert K, Dinsart C, Rommelaere J, Foerster F, Moehler M.

Front Oncol. 2019 May 28;9:425. doi: 10.3389/fonc.2019.00425. eCollection 2019.


Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.

Lacroix J, Kis Z, Josupeit R, Schlund F, Stroh-Dege A, Frank-Stöhr M, Leuchs B, Schlehofer JR, Rommelaere J, Dinsart C.

Viruses. 2018 Jun 3;10(6). pii: E302. doi: 10.3390/v10060302.


Mutations in the Non-Structural Protein-Coding Sequence of Protoparvovirus H-1PV Enhance the Fitness of the Virus and Show Key Benefits Regarding the Transduction Efficiency of Derived Vectors.

Hashemi H, Condurat AL, Stroh-Dege A, Weiss N, Geiss C, Pilet J, Cornet Bartolomé C, Rommelaere J, Salomé N, Dinsart C.

Viruses. 2018 Mar 27;10(4). pii: E150. doi: 10.3390/v10040150.


Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.

Geiss C, Kis Z, Leuchs B, Frank-Stöhr M, Schlehofer JR, Rommelaere J, Dinsart C, Lacroix J.

Viruses. 2017 Oct 17;9(10). pii: E301. doi: 10.3390/v9100301.


Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle.

Dinsart C, Pervolaraki K, Stroh-Dege A, Lavie M, Ronsse I, Rommelaere J, Van Damme J, Van Raemdonck K, Struyf S.

Hum Gene Ther. 2017 Mar;28(3):295-306. doi: 10.1089/hum.2016.108. Epub 2016 Dec 29.


Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment.

Higareda-Almaraz JC, Ruiz-Moreno JS, Klimentova J, Barbieri D, Salvador-Gallego R, Ly R, Valtierra-Gutierrez IA, Dinsart C, Rabinovich GA, Stulik J, Rösl F, Rincon-Orozco B.

BMC Cancer. 2016 Aug 24;16:680. doi: 10.1186/s12885-016-2700-8.


Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.

Josupeit R, Bender S, Kern S, Leuchs B, Hielscher T, Herold-Mende C, Schlehofer JR, Dinsart C, Witt O, Rommelaere J, Lacroix J.

Viruses. 2016 May 19;8(5). pii: E138. doi: 10.3390/v8050138.


Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis.

Lavie M, Struyf S, Stroh-Dege A, Rommelaere J, Van Damme J, Dinsart C.

Virology. 2013 Dec;447(1-2):221-32. doi: 10.1016/j.virol.2013.09.019. Epub 2013 Oct 4.


Parvoviruses cause nuclear envelope breakdown by activating key enzymes of mitosis.

Porwal M, Cohen S, Snoussi K, Popa-Wagner R, Anderson F, Dugot-Senant N, Wodrich H, Dinsart C, Kleinschmidt JA, Panté N, Kann M.

PLoS Pathog. 2013 Oct;9(10):e1003671. doi: 10.1371/journal.ppat.1003671. Epub 2013 Oct 31.


Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids.

Halder S, Nam HJ, Govindasamy L, Vogel M, Dinsart C, Salomé N, McKenna R, Agbandje-McKenna M.

J Virol. 2013 May;87(9):5128-40. doi: 10.1128/JVI.03416-12. Epub 2013 Feb 28.


Production, purification, crystallization and structure determination of H-1 Parvovirus.

Halder S, Nam HJ, Govindasamy L, Vogel M, Dinsart C, Salomé N, McKenna R, Agbandje-McKenna M.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Dec 1;68(Pt 12):1571-6. doi: 10.1107/S1744309112045563. Epub 2012 Nov 28.


Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.

Sieben M, Schäfer P, Dinsart C, Galle PR, Moehler M.

Int J Cancer. 2013 Jun 1;132(11):2548-56. doi: 10.1002/ijc.27938. Epub 2012 Nov 29.


Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.

Dempe S, Lavie M, Struyf S, Bhat R, Verbeke H, Paschek S, Berghmans N, Geibig R, Rommelaere J, Van Damme J, Dinsart C.

Cancer Immunol Immunother. 2012 Nov;61(11):2113-23. doi: 10.1007/s00262-012-1279-4. Epub 2012 May 11.


An in-frame deletion in the NS protein-coding sequence of parvovirus H-1PV efficiently stimulates export and infectivity of progeny virions.

Weiss N, Stroh-Dege A, Rommelaere J, Dinsart C, Salomé N.

J Virol. 2012 Jul;86(14):7554-64. doi: 10.1128/JVI.00212-12. Epub 2012 May 2.


Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.

Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR.

BMC Cancer. 2011 Oct 26;11:464. doi: 10.1186/1471-2407-11-464.


Enhancement of NK cell antitumor responses using an oncolytic parvovirus.

Bhat R, Dempe S, Dinsart C, Rommelaere J.

Int J Cancer. 2011 Feb 15;128(4):908-19. doi: 10.1002/ijc.25415.


Oncolytic parvoviruses as cancer therapeutics.

Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. doi: 10.1016/j.cytogfr.2010.02.011. Epub 2010 Mar 7. Review.


SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.

Dempe S, Stroh-Dege AY, Schwarz E, Rommelaere J, Dinsart C.

Int J Cancer. 2010 Jun 15;126(12):2914-27. doi: 10.1002/ijc.24992.


Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects.

Struyf S, Proost P, Vandercappellen J, Dempe S, Noyens B, Nelissen S, Gouwy M, Locati M, Opdenakker G, Dinsart C, Van Damme J.

Eur J Immunol. 2009 Mar;39(3):843-57. doi: 10.1002/eji.200838660.


Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.

Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z.

Clin Cancer Res. 2009 Jan 15;15(2):511-9. doi: 10.1158/1078-0432.CCR-08-1088.


TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma.

Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R, Kiessling F, Paschek S, Sozzani S, Rommelaere J, Cornelis JJ, Van Damme J, Dinsart C.

Cancer Gene Ther. 2009 Feb;16(2):149-60. doi: 10.1038/cgt.2008.62. Epub 2008 Aug 1.


Augmented transgene expression in transformed cells using a parvoviral hybrid vector.

Krüger L, Eskerski H, Dinsart C, Cornelis J, Rommelaere J, Haberkorn U, Kleinschmidt JA.

Cancer Gene Ther. 2008 Apr;15(4):252-67. doi: 10.1038/sj.cgt.7701113. Epub 2008 Jan 18.


MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells.

Wetzel K, Struyf S, Van Damme J, Kayser T, Vecchi A, Sozzani S, Rommelaere J, Cornelis JJ, Dinsart C.

Int J Cancer. 2007 Mar 15;120(6):1364-71.


Humoral immune responses against minute virus of mice vectors.

Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ.

J Gene Med. 2006 Sep;8(9):1141-50.


The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different.

Lang SI, Boelz S, Stroh-Dege AY, Rommelaere J, Dinsart C, Cornelis JJ.

J Virol. 2005 Jan;79(1):289-98.


Cancer gene therapy through autonomous parvovirus--mediated gene transfer.

Cornelis JJ, Lang SI, Stroh-Dege AY, Balboni G, Dinsart C, Rommelaere J.

Curr Gene Ther. 2004 Sep;4(3):249-61. Review.


Vectors based on autonomous parvoviruses: novel tools to treat cancer?

Cornelis JJ, Salomé N, Dinsart C, Rommelaere J.

J Gene Med. 2004 Feb;6 Suppl 1:S193-202. Review.


Production of recombinant H1 parvovirus stocks devoid of replication-competent viruses.

Brown CS, DiSumma FM, Rommelaere J, Dege AY, Cornelis JJ, Dinsart C, Spaan WJ.

Hum Gene Ther. 2002 Dec 10;13(18):2135-45.


Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice.

Giese NA, Raykov Z, DeMartino L, Vecchi A, Sozzani S, Dinsart C, Cornelis JJ, Rommelaere J.

Cancer Gene Ther. 2002 May;9(5):432-42.


Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin.

Olijslagers S, Dege AY, Dinsart C, Voorhoeve M, Rommelaere J, Noteborn MH, Cornelis JJ.

Cancer Gene Ther. 2001 Dec;8(12):958-65.


Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts.

Wetzel K, Menten P, Opdënakker G, Van Damme J, Gröne HJ, Giese N, Vecchi A, Sozzani S, Cornelis JJ, Rommelaere J, Dinsart C.

J Gene Med. 2001 Jul-Aug;3(4):326-37.


cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses.

Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D'Abramo A, Tattersall P, Rommelaere J, Dinsart C, Cornelis JJ.

Hum Gene Ther. 1999 Jul 1;10(10):1619-32.


Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection.

López-Guerrero JA, Rayet B, Tuynder M, Rommelaere J, Dinsart C.

Blood. 1997 Mar 1;89(5):1642-53.


A gene from the variant surface glycoprotein expression site encodes one of several transmembrane adenylate cyclases located on the flagellum of Trypanosoma brucei.

Paindavoine P, Rolin S, Van Assel S, Geuskens M, Jauniaux JC, Dinsart C, Huet G, Pays E.

Mol Cell Biol. 1992 Mar;12(3):1218-25.


The orphan receptor cDNA RDC4 encodes a 5-HT1D serotonin receptor.

Maenhaut C, Van Sande J, Massart C, Dinsart C, Libert F, Monferini E, Giraldo E, Ladinsky H, Vassart G, Dumont JE.

Biochem Biophys Res Commun. 1991 Nov 14;180(3):1460-8.


Antibodies to human thyroid peroxidase in autoimmune thyroid disease: studies with a cloned recombinant complementary deoxyribonucleic acid epitope.

Ludgate M, Mariotti S, Libert F, Dinsart C, Piccolo P, Santini F, Ruf J, Pinchera A, Vassart G.

J Clin Endocrinol Metab. 1989 Jun;68(6):1091-6.


Selective amplification and cloning of four new members of the G protein-coupled receptor family.

Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, Simons MJ, Dumont JE, Vassart G.

Science. 1989 May 5;244(4904):569-72.


RFLPs detected at 2 pter-p12 with a thyroid peroxidase cDNA probe, TPO3 (McKusick no. 27450).

Massaro G, Libert F, Vassart G, Dinsart C.

Nucleic Acids Res. 1989 Mar 11;17(5):2155. No abstract available.


Regional localization of the gene for thyroid peroxidase to human chromosome 2pter----p12.

de Vijlder JJ, Dinsart C, Libert F, Geurts van Kessel A, Bikker H, Bolhuis PA, Vassart G.

Cytogenet Cell Genet. 1988;47(3):170-2.


Thyroperoxidase, an auto-antigen with a mosaic structure made of nuclear and mitochondrial gene modules.

Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G, Dinsart C.

EMBO J. 1987 Dec 20;6(13):4193-6.


Complete nucleotide sequence of the human thyroperoxidase-microsomal antigen cDNA.

Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G, Dinsart C.

Nucleic Acids Res. 1987 Aug 25;15(16):6735. No abstract available.


Differential effect of ultraviolet light on the induction of simian virus 40 and a cellular mutator phenotype in transformed mammalian cells.

Dinsart C, Cornelis JJ, Decaesstecker M, van der Lubbe J, van der Eb AJ, Rommelaere J.

Mutat Res. 1985 Aug;151(1):9-14.


Transfection with extracellularly UV-damaged DNA induces human and rat cells to express a mutator phenotype towards parvovirus H-1.

Dinsart C, Cornelis JJ, Klein B, van der Eb AJ, Rommelaere J.

Mol Cell Biol. 1984 Feb;4(2):324-8.


Interrelation between viral and cellular DNA synthesis in mouse cells infected with the parvovirus minute virus of mice.

Hardt N, Dinsart C, Spadari S, Pedrali-Noy G, Rommelaere J.

J Gen Virol. 1983 Sep;64 (Pt 9):1991-8.


Supplemental Content

Loading ...
Support Center